Epidemiology of herpes simplex
The epidemiology of herpes simplex is of substantial epidemiologic and public health interest. Worldwide, the rate of infection with herpes simplex virus—counting both HSV-1 and HSV-2—is around 90%. Although many people infected with HSV develop labial or genital lesions (herpes simplex), the majority are either undiagnosed or display no physical symptoms—individuals with no symptoms are described as asymptomatic or as having subclinical herpes.
In many infections, the first symptom a person will have of their own infection is the horizontal transmission to a sexual partner or the vertical transmission of neonatal herpes to a newborn at term. Since most asymptomatic individuals are unaware of their infection, they are considered at high risk for spreading HSV. Many studies have been performed around the world to estimate the numbers of individuals infected with HSV-1 and HSV-2 by determining if they have developed antibodies against either viral species.
This information provides population prevalence of HSV viral infections in individuals with or without active disease. It has to be remembered that there are population subgroups that are more vulnerable for HSV infections, such as cancer chemotherapy patients.
|Seroprevalence estimates for HSV-1 and HSV-2|
|Central African Republic||1998–9||99||82||–|
|# in children|
|* Ages 12-70|
Large differences in HSV-1 seroprevalence are seen in different European countries. HSV-1 seroprevalence is high in Bulgaria (83.9%) and The Czech Republic (80.6%), and lower in Belgium (67.4%), The Netherlands (56.7%), and Finland (52.4%).
The typical age at which HSV-1 infection is acquired ranges from 5 to 9 years in Central and Eastern European countries like Bulgaria and the Czech Republic, to over 25 years of age in Northern European countries such as Finland, The Netherlands, Germany, and England and Wales. Young adults in Northern European countries are less likely to be infected with HSV-1. European women are more likely to be HSV-1 seropositive than men.
HSV-2 seropositivity is widely distributed in Europeans older than 12, although there are large differences in the percentage of the population exposed to HSV-2. Bulgaria has a high (23.9%) HSV-2 seroprevalence relative to other European countries: Germany (13.9%), Finland (13.4%), Belgium (11.1%), The Netherlands (8.8%), the Czech Republic (6.0%), and England and Wales (4.2%).
Women are more likely to be seropositive than men, and likely acquire the virus at an earlier age. In each country of Europe, HSV-2 seropositivity becomes more common from adolescence onwards and increases in the population with age, with a decline in the older age groups in some countries.
The most recent data for HSV-2 was published in March 2010, based on a National Health and Nutrition Examination Survey study performed between 2005 and 2013 by CDC. About 1 in 6 Americans (16.2%) aged 14 to 49 is infected with HSV-2. HSV-2 prevalence was nearly twice as high among women (20.9%) than men (11.5%), and was more than three times higher among blacks (39.2%) than non-Hispanic whites (12.3%).
The most affected group was black women, with a prevalence rate of 48%. Prevalence increased with age and number of partners. Only 18.9% of those infected had previously been aware of their infection.
|Age: 14–19 yrs||1.4%||2.1%||0.8%|
|Age: 20–29 yrs||10.5%||14.4%||6.6%|
|Age: 30–39 yrs||19.6%||25.2%||13.9%|
|Age: 40–49 yrs||26.1%||32.3%||19.6%|
|Ethnicity: White, non-Hispanic||12.3%||15.9%||8.7%|
|Ethnicity: Black, non-Hispanic||39.2%||48.0%||29.0%|
|Ethnicity: Mexican American||10.1%||13.2%||7.5%|
|1 Lifetime Sex Partner||3.9%||5.4%||1.7%|
|2–4 Lifetime Sex Partners||14.0%||18.8%||7.3%|
|5–9 Lifetime Sex Partners||16.3%||21.8%||10.1%|
|>10 Lifetime Sex Partners||26.7%||37.1%||19.1%|
African Americans and immigrants from developing countries typically have an HSV-1 seroprevalance in their adolescent population that is two or three times higher than that of Caucasian Americans. Many white Americans become sexually active while seronegative for HSV-1. The absence of antibodies from a prior oral HSV-1 infection leaves these individuals susceptible to herpes whitlow, herpes gladiatorum, and HSV-1 genital infection. Primary genital infection brings with it the risk of vertical transmission to the neonate, and is highest if the mother contracts a primary infection during the third trimester of pregnancy. In the U.S. the number of genital infections caused by HSV-1 is now thought to be about 50% of first episodes of genital infection.
In healthy adults, HSV-2 infection occurs more frequently in the United States than in Europe.
Seroprevalence rates in the United States appeared to be increasing, rising from 16.4% in 1976 to 21.8% in 1994. However, this trend seems to have reversed itself in recent years, dropping to 17.2% in 2004.
The current prevalence of genital herpes caused by HSV-2 in the U.S. is roughly one in four or five adults, with approximately 50 million people infected with genital herpes and an estimated 0.5 million new genital herpes infections occurring each year. African Americans appear more susceptible to HSV-2, although the presence of active genital symptoms is more likely in Caucasian Americans. The largest increase in HSV-2 acquisition during the past few years is in white adolescents. People with many lifetime sexual partners and those who are sexually active from a young age are also at higher-risk for the transmission of HSV-2 in the U.S.
Women are at higher risk than men for acquiring HSV-2 infection, and the chance of being infected increases with age. The CDC reports that 48% of African American women in the United States are infected with the HSV-2 virus. 
According to a study in Ontario, of people between the ages of 15 to 16, 26.9% of men, 32% of non-pregnant women, and 55% of pregnant women tested positive for HSV-1 antibodies. Between the ages of 40 to 44, 54.7% of men, 88.7% of women, and 69.2% of pregnant women tested positive for HSV-1 antibodies. The overall age-gender standardized seroprevelance for HSV-1 antibodies was 51.1%. Teenagers are less likely to be seropositive for HSV-2—antibodies against this virus are only found in 0–3.8% of 15- and 16-year-olds. However, 21% of individuals in their early forties have antibodies against HSV-2, reflecting the sexually transmitted nature of this virus. When standardising for age, HSV-2 seroprevalence in Ontario for individuals between the ages of 15 to 44 was 9.1%. Rates for Canadian people infected with HSV-2 is much lower than estimated levels of HSV-2 seroprevalence in people of a similar age range in the United States.
HSV-2 seroprevalence in pregnant women between the ages of 15–44 in British Columbia is similar, with 57% having antibodies for HSV-1 and 13% having antibodies for HSV-2. In British Columbia in 1999, the seroprevalence of HSV-2 antibody in leftover serum submitted for antenatal testing revealed a prevalence of 17.3%, ranging from 7.1% in women 15–19 years old to 28.2% in those 40–44 years. • In attendees at an Alberta sexually transmitted infection (STI) clinic in 1994 and 1995, the seroprevalence of HSV-1 and -2 in leftover sera was 56% and 19%, respectively. In Nova Scotia, 58.1% of 1,790 HSV isolates from genital lesion cultures in women were HSV-1; in men, 36.7% of 468 isolates were HSV-1
HSV-2 is more common in Sub-Saharan Africa than in Europe or the North America. Up to 82% of women and 53% of men in Sub-Saharan Africa are seropositive for HSV-2. These are the highest levels of HSV-2 infection in the world, although exact levels vary from country to country in this continent.
In most African countries, HSV-2 prevalence increases with age. However, age-associated decreases in HSV-2 seroprevalence has been observed for women in Uganda and Zambia, and in men in Ethiopia, Benin, and Uganda.
Genital herpes appears less common in Northern Africa compared to Sub-Saharan Africa. For example, only 26% of middle-aged women have antibodies for HSV-2 in Morocco. Women are more likely to be infected with HSV-2 once they are over the age of 40.
Children in Egypt with acute lymphoblastic leukemia are often infected with HSV from a young age—HSV-1 or HSV-2 antibodies are present in an estimated 54% of children under the age of 5, and 77% in children over 10 years of age.Algerian children are also likely to acquire HSV-1 infection at a young age (under 6) and 81.25% of the population has antibodies to HSV-1 by the age of 15.
Central and South AmericaEdit
Relative to rates in Europe and North America, HSV-2 seroprevalency is high in Central and South America. Infection levels are estimated at 20% to 60%. During the mid-1980s, HSV-2 prevalence was 33% in 25- to 29-year-old women and 45% in those aged 40 and over in Costa Rica. In the early 1990s HSV-2 prevalence was approximately 45% among women over 60 in Mexico.
The highest HSV-2 prevalence in Central or South America—60%—has been found in Colombian middle-aged women, although similar HSV-2 prevalence has been observed in younger women in Haiti (54%). HSV-2 infects about 30% of women over 30 years old in Colombia, Costa Rica, Mexico, and Panama. HSV-2 antibodies were found in more than 41% of women of childbearing age in Brazil.
However, no increase in seroprevalence was associated with age in women over 40 years old in Brazil—HSV-2 prevalence was estimated at 50% among women aged 40–49, 33% among women 50–59, and 42% among women over 60. Women in Brazil are more likely to acquire an HSV-2 infection if their male partners had history of anal sex and had many sexual partners in his lifetime. In Peru, HSV-2 prevalence is also high among women in their 30s but is lower in men.
Eastern and South East AsiaEdit
HSV-1 seroprevalence in some Asian countries is low, relative to other countries worldwide, with only 51% women in Thailand, and between 50–60% in Japan possessing antibodies. HSV-2 seroprevalence in developing Asian countries is comparable (10–30%) to that observed in North America and Northern Europe. However, estimates of HSV-2 infectivity in Thailand are higher than observed in other Eastern Asian countries; total HSV-2 seroprevalence is approximately 37% in this country. HSV-2 seroprevalence is low in women in the Philippines (9%), although commencing activity while young is associated with an increase risk of acquiring HSV-2 infection; woman starting sexual activity by the time they reach 17 are seven times more likely to be HSV-2 seropositive than those starting sexual activity when over 21.
In South Korea, incidence of HSV-2 infection in those under the age of 20 is low, only 2.7% in men and 3.0% in women. Seroprevalence levels increase in older South Koreans however, such that the population over 20 that has antibodies against HSV-2 is 21.7% of men and 28% of women.
In India 33.3% of individuals are seropositive for HSV-1 and 16.6% are seropositive for HSV-2. Those with both HSV-1 and HSV-2 antibodies are estimated at 13.3% of the population. Indian men are more likely to be infected with HSV-2 than women, and increasing seroprevalence of this virus is associated with an increasing age.
Turkey— High levels of HSV-1 (97%) and HSV-2 (42%) were found amongst pregnant women in the city of Erzurum in Eastern Anatolia Region, Turkey. In Istanbul however, lower HSV-2 seroprevalence was observed; HSV-2 antibodies were found in 4.8% of sexually active adults, while HSV-1 antibodies were found in 85.3%. Only 5% of pregnant women were infected with HSV-2, and 98% were infected with HSV-1. Prevalence of these viruses was higher in sex workers of Istanbul, reaching levels of 99% and 60% for HSV-1 and HSV-2 prevalence respectively.
Israel— HSV-1 seroprevalence is 59.8% in the population of Israel and increases with age in both genders but the adolescent seroprevalence has been declining as in most industrialized nations. An estimated 9.2% of Israeli adults are infected with HSV-2. Infection of either HSV-1 or HSV-2 is higher in females; HSV-2 seroprevalence reaches 20.5% in females in their 40s. These values are similar to levels in HSV infection in Europe.
Antibodies for HSV-1 or HSV-2 are also more likely to be found individuals born outside of Israel, and individuals residing in Jerusalem and Southern Israel; people of Jewish origin living in Israel are less likely to possess antibodies against herpes. Among pregnant women in Israel a small scale cross sectional study found the prevalence of HSV-2 infection was 13.3% and that of HSV-1 was 94.9%. The HSV-2 infection rate was 3-fold higher among immigrants from the former Soviet Union (27.5%) than among Israeli-born Jewish and Arab women (9%). Approximately 78% of HSV-2 infections in Israel are asymptomatic. HSV-1 causes 66.3% of genital herpes in the Tel Aviv area.
Syria— Genital herpes infection from HSV-2 is predicted to be low in Syria although HSV-1 levels are high. HSV-1 infections is common (95%) among healthy Syrians over the age of 30, while HSV-2 prevalence is low in healthy individuals (0.15%), and persons infected with other sexually transmitted diseases (9.5%). High risk groups for acquiring HSV-2 in Syria, include prostitutes and bar girls; they have 34% and 20% seroprevalence respectively.
In Australia, a study using data from 1999 revealed the seroprevalence of HSV-1 was at 76.5%, with significant differences associated with age, gender and Indigenous status, which were not specified. An estimated 12% of Australian adults were seropositive for HSV-2, with higher prevalence in women (16%) than in men (8%). Larger cities had higher HSV-2 seroprevalence (13%) than rural populations (9%). Higher prevalence was found in Indigenous Australians (18%) than non-Indigenous Australians (12%).
As in the U.S., HSV-1 is increasingly identified as the cause of genital herpes in Australians; HSV-1 was identified in the anogenital area of only 3% of the population in 1980, but had risen to 41% in 2001. This was most common in females and persons under 25. The number of genital herpes infections appears to be rising in New Zealand with three times more cases in 1993 compared to 1977. In this country, HSV-2 affects 60% more women than men of similar age.
- Wald, Anna; Corey, Lawrence (2007). "Chapter 36: Persistence in the population: epidemiology, transmission". Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge University Press. ISBN 978-0-521-82714-0.
- Handsfield HH (2000). "Public Health Strategies to Prevent Genital Herpes: Where Do We Stand?". Curr Infect Dis Rep. 2 (1): 25–30. doi:10.1007/s11908-000-0084-y. PMID 11095834.
- Smith JS, Robinson NJ (2002). "Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review". J. Infect. Dis. 186 Suppl 1: S3–28. doi:10.1086/343739. PMID 12353183.
- Elad S, Zadik Y, Hewson I, et al. (August 2010). "A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea". Support Care Cancer. 18 (8): 993–1006. doi:10.1007/s00520-010-0900-3. PMID 20544224.
- Patnaik P, Herrero R, Morrow RA, et al. (2007). "Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study". Sex Transm Dis. 34 (12): 1019–24. PMID 18080353.
- Shin HS, Park JJ, Chu C, et al. (2007). "Herpes simplex virus type 2 seroprevalence in Korea: rapid increase of HSV-2 seroprevalence in the 30s in the southern part". J. Korean Med. Sci. 22 (6): 957–62. doi:10.3346/jkms.2007.22.6.957. PMC 2694633. PMID 18162706.
- Pebody RG, Andrews N, Brown D, et al. (2004). "The seroepidemiology of herpes simplex virus type 1 and 2 in Europe". Sex Transm Infect. 80 (3): 185–91. doi:10.1136/sti.2003.005850. PMC 1744847. PMID 15170000.
- Xu F, Sternberg MR, Gottlieb SL, Berman SM, Markowitz LE, Forhan SE, Taylor (23 April 2010). "Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14–49 Years—United States, 2005–2013". Morbidity and Mortality Weekly Report (MMWR). 59 (15): 456–459. PMID 20414188. Retrieved 12 April 2011.
- Fatahzadeh M, Schwartz RA (2007). "Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management". J. Am. Acad. Dermatol. 57 (5): 737–63, quiz 764–6. doi:10.1016/j.jaad.2007.06.027. PMID 17939933.
- Mertz GJ, Rosenthal SL, Stanberry LR (October 2003). "Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes?". Sex Transm Dis. 30 (10): 801–2. doi:10.1097/01.OLQ.0000093080.55201.D1. PMID 14520182.
- Roberts CM, Pfister JR, Spear SJ (2003). "Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students" (PDF). Sex Transm Dis. 30 (10): 797–800. doi:10.1097/01.OLQ.0000092387.58746.C7. PMID 14520181.
- Malkin JE (2004). "Epidemiology of genital herpes simplex virus infection in developed countries" (PDF). Herpes. 11 Suppl 1: 2A–23A. PMID 15115626.
- Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE (2006-10-23). "Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States". JAMA. AMA. 296 (8): 964–73. doi:10.1001/jama.296.8.964. PMID 16926356.
- "Herpes simplex". University of Maryland Medical Center. Retrieved 2007-09-03.
- "LEARN ABOUT HERPES > Fast Facts". ASHA Herpes Resource Center. Archived from the original on 2007-09-14. Retrieved 2007-09-03.
- "STD Facts – Genital Herpes". Centers for Disease Control and Prevention. Retrieved 2007-09-03.
- "Herpes". Stanford University Sexual Health Peer Resource Center. Archived from the original on 2007-10-11. Retrieved 2007-09-03.
- "CDC: Genital Herpes Rates Still High". Centers for Disease Control and Prevention. Retrieved 2011-02-03.
- "UPDATE: CDC Stands Behind Report That Half of BLack Women Have Herpes". NewsOne. 2010-04-22. Retrieved 2011-02-03.
- Howard M, Sellors JW, Jang D, et al. (January 2003). "Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada". J Clin Microbiol. 41 (1): 84–9. doi:10.1128/JCM.41.1.84-89.2003. PMC 149555. PMID 12517830.
- Patrick DM, Dawar M, Cook DA, Krajden M, Ng HC, Rekart ML (July 2001). "Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years". Sex Transm Dis. 28 (7): 424–8. doi:10.1097/00007435-200107000-00011. PMID 11460028.
- Singh AE, Romanowski B, Wong T, et al. (February 2005). "Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics". Sex Transm Dis. 32 (2): 95–100. doi:10.1097/01.olq.0000151415.78210.85. PMID 15668615.
- Forward KR, Lee SH (March 2003). "Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova Scotia". Can J Infect Dis. 14 (2): 94–6. doi:10.1155/2003/168673. PMC 2094909. PMID 18159431.
- Weiss H (2004). "Epidemiology of herpes simplex virus type 2 infection in the developing world". Herpes. 11 Suppl 1: 24A–35A. PMID 15115627.
- Loutfy SA, Alam El-Din HM, Ibrahim MF, Hafez MM (2006). "Seroprevalence of herpes simplex virus types 1 and 2, Epstein–Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt Kundi". Saudi Med J. 27 (8): 1139–45. PMID 16883441.
- Meguenni S, Djenaoui T, Bendib A, et al. (1989). "Herpes simplex virus infections in Algiers". Arch Inst Pasteur Alger (in French). 57: 61–72. PMID 2562258.
- Smith JS, Herrero R, Muñoz N, et al. (2001). "Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines". Sex Transm Dis. 28 (4): 187–94. doi:10.1097/00007435-200104000-00001. PMID 11318248.
- Kaur R, Gupta N, Baveja UK (2005). "Seroprevalence of HSV1 and HSV2 infections in family planning clinic attenders". J Commun Dis. 37 (4): 307–9. PMID 17278662.
- Dolar N, Serdaroglu S, Yilmaz G, Ergin S (2006). "Seroprevalence of herpes simplex virus type 1 and type 2 in Turkey". J Eur Acad Dermatol Venereol. 20 (10): 1232–6. doi:10.1111/j.1468-3083.2006.01766.x. PMID 17062037.
- Abuharfeil N, Meqdam MM (2000). "Seroepidemiologic study of herpes simplex virus type 2 and cytomegalovirus among young adults in northern Jordan". New Microbiol. 23 (3): 235–9. PMID 10939038.
- Davidovici BB, Grotto I, Balicer RD, Robinson NJ, Cohen D (November 2006). "Decline in the prevalence of antibodies to herpes simplex virus types 1 and 2 among Israeli young adults between 1984 and 2002" (PDF). Sex Transm Dis. 33 (11): 641–5. doi:10.1097/01.olq.0000216068.01028.38. PMID 16614586.
- Davidovici BB, Green M, Marouni MJ, Bassal R, Pimenta JM, Cohen D (2006). "Seroprevalence of herpes simplex virus 1 and 2 and correlates of infection in Israel". J. Infect. 52 (5): 367–73. doi:10.1016/j.jinf.2005.08.005. PMID 16213591.
- Dan M; Sadan O.; Glezerman M; Raveh D; Samra Z (2003). "Prevalence and risk factors for herpes simplex virus type 2 infection among pregnant women in Israel" (PDF). Sex Transm Dis. 30 (11): 835–8. doi:10.1097/01.OLQ.0000086608.07893.1A. PMID 14603091.
- Feldman PA, Steinberg J, Madeb R, et al. (September 2003). "Herpes simplex virus type 2 seropositivity in a sexually transmitted disease clinic in Israel" (PDF). Isr. Med. Assoc. J. 5 (9): 626–8. PMID 14509150.
- Samra Z, Scherf E, Dan M (2003). "Herpes simplex virus type 1 is the prevailing cause of genital herpes in the Tel Aviv area, Israel". Sex Transm Dis. 30 (10): 794–6. doi:10.1097/01.OLQ.0000079517.04451.79. PMID 14520180.
- Ibrahim AI, Kouwatli KM, Obeid MT (2000). "Frequency of herpes simplex virus in Syria based on type-specific serological assay". Saudi Med J. 21 (4): 355–60. PMID 11533818.
- Cunningham AL, Taylor R, Taylor J, Marks C, Shaw J, Mindel A (2006). "Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey". Sex Transm Infect. 82 (2): 164–8. doi:10.1136/sti.2005.016899. PMC 2564694. PMID 16581748.
- Haddow LJ, Dave B, Mindel A, et al. (2006). "Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003". Sex Transm Infect. 82 (3): 255–9. doi:10.1136/sti.2005.018176. PMC 2564751. PMID 16731681.
- Lyttle PH (1994). "Surveillance report: disease trends at New Zealand sexually transmitted disease clinics 1977–1993". Genitourin Med. 70 (5): 329–35. doi:10.1136/sti.70.5.329. PMC 1195277. PMID 8001945.